Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden · Delayed Price · Currency is SEK 197.40
-2.80 (-1.40%)
Aug 1, 2025, 5:29 PM CET
Xvivo Perfusion AB Revenue
Xvivo Perfusion AB had revenue of 178.30M SEK in the quarter ending June 30, 2025, a decrease of -15.24%. This brings the company's revenue in the last twelve months to 822.93M, up 17.78% year-over-year. In the year 2024, Xvivo Perfusion AB had annual revenue of 822.42M with 37.63% growth.
Revenue (ttm)
822.93M
Revenue Growth
+17.78%
P/S Ratio
7.56
Revenue / Employee
4.26M
Employees
190
Market Cap
6.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 822.42M | 224.87M | 37.63% |
| Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
| Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
| Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
| Dec 31, 2020 | 179.86M | -40.98M | -18.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.97B |
| Sectra AB | 3.31B |
| Getinge AB | 35.50B |
| Medicover AB | 25.22B |
| Camurus AB | 2.27B |
| Asker Healthcare Group AB | 15.88B |
| Bonesupport Holding AB | 1.06B |
| AddLife AB | 10.44B |
Xvivo Perfusion AB News
- 22 days ago - Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing ... - GuruFocus
- 22 days ago - Q2 2025 Xvivo Perfusion AB Earnings Call Transcript - GuruFocus